UroGen Pharma logo

UroGen Pharma

URGN | NASDAQ
Chart Builder DCF Calculator
$28.10
+$1.92 (+7.33%)
At close: Nov 16, 2026, 4:00 PM ET
$27.54
-$0.56 (-1.99%)
After-hours: Nov 16, 2026, 7:30 PM ET
+7.33%

Rating

Updated: Nov 16, 2026
48.7
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #316/1021 (Top 31%)

Key Statistics

Market Data

Market Cap $1.38B
1D Range
23.19 29.50
52W Range
17.00 50.29

Valuation (TTM)

PE -21.29
PB -11.01
EV/EBITDA -37.20

Valuation (NTM)

Forward PE 10.08
Forward PEG 0.22
Price Target $58.00
Loading financial charts...

Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompa...

Sector Healthcare
Industry Biotechnology
Employees 300
IPO Date May 4, 2017
Fiscal Year January - December

Latest News

UroGen: Opportunity Builds As Rough Patch Gets Brutal

8 days ago · seekingalpha.com

UroGen: Opportunity Builds As Rough Patch Gets Brutal
Urogen Pharma Q3 Earnings Call Highlights

12 days ago · marketbeat.com

Urogen Pharma Q3 Earnings Call Highlights
The Gel That Became a Business

12 days ago · fool.com

The Gel That Became a Business
UroGen Pharma Ltd. (URGN) Q3 2026 Earnings Call Transcript

12 days ago · seekingalpha.com

UroGen Pharma Ltd. (URGN) Q3 2026 Earnings Call Transcript
Urogen Pharma (URGN) Reports Q3 Loss, Beats Revenue Estimates

13 days ago · zacks.com

Urogen Pharma (URGN) Reports Q3 Loss, Beats Revenue Estimates
UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights

13 days ago · globenewswire.com

UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights
UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

14 days ago · globenewswire.com

UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

15 days ago · globenewswire.com

UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026

20 days ago · globenewswire.com

UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026
UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC

29 days ago · globenewswire.com

UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC

Earnings

Latest Earnings
Nov 4, 2026
EPS
-$0.03
Miss -128.38%
REV
$89M
Miss -1.02%
Next Earnings
Mar 1, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
5
Consensus
Buy
Price Target
$58.00
Upside
+106.41%
Buy (5)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.